Skip to content Skip to footer
Subscribe Now
Bio-Thera Solutions Expands its Partnership with STADA for BAT1806 (Biosimilar, RoActemra)
NEWS

STADA & Bio-Thera Receive the EC approval for Gotenfia (Biosimilar, Simponi)

Shots: The EC has approved STADA & Bio-Thera’s Gotenfia (BAT2506; 50mg/0.5mL & 100mg/mL PFS), a biosimilar version of Simponi (golimumab), in all 30 EEA states, with launch preparations ongoing Approval was based on extensive analytical, non-clinical & clinical data demonstrating biosimilarity of BAT2506 to Simponi In May 2024 deal, STADA obtained exclusive commercial rights to Gotenfia…
February 16, 2026

Read more

Bio-Thera Solutions Expands its Partnership with STADA for BAT1806 (Biosimilar, RoActemra)
NEWS

Bio-Thera Solutions Expands its Partnership with STADA for BAT1806 (Biosimilar, RoActemra)

Shots: Bio-Thera & STADA have expanded their partnership to BAT1806, a biosimilar version of Roche’s RoActemra (tocilizumab), whose 20mg/ml vial formulation received EMA’s approval in Jun 2024 for several arthritic conditions As per the deal, STADA will obtain exclusive rights to commercialize BAT1806 in the EU, UK, Switzerland & select other countries under its own marketing…
August 25, 2025

Read more

2025 BioPharma Deals: The Survival Series | Nov 24-25 | Munich, Germany
EVENTS

2025 BioPharma Deals: The Survival Series | Nov 24-25 | Munich, Germany

BioPharma Deals: The Survival Series brings together leaders from biotech, pharma, investment, CRO/CDMO, legal, and advisory sectors for a high-impact event focused on pragmatic deal-making, new financing models, early IPOs, and unconventional partnerships. This is not a conference about the distant future. It's a working summit for what can be done now. It's about survival,…
August 18, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …
July 15, 2024

Read more

VIEWPOINTS_Raviv Pryluk_2024
VIEWPOINTS

Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace

Shots:   Raviv Pryluk, CEO and Co-Founder of PhaseV, in a stimulating conversation with PharmaShots, sheds light on the company’s recent partnership with 9xchange Biopharma    The partnership aims to bring Phase V’s proprietary machine learning (ML) technology to ecosystem members, enabling them, to retrospectively analyze and optimally design and execute advanced clinical studies   Raviv highlights the…
April 23, 2024

Read more

VIEWPOINTS_Brian Quigley_2024
VIEWPOINTS

Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia

Shots:  Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots   The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio   During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…
January 8, 2024

Read more

VIEWPOINTS_Justin Schreiber_2023
VIEWPOINTS

Justin Schreiber Discusses the Recently Launched D2C Telehealth Model for Hormone Therapy

Shots:   Justin Schreiber, Chairman, and CEO of, LifeMD, in an illuminating conversation with PharmaShots, discusses the recent partnership with ASCEND Therapeutics    LifeMD, a virtual primary care company, and ASCEND Therapeutics, a leading women's health pharmaceutical company, came together to bring an integrated direct-to-consumer telehealth model to enhance the way women receive care for their menopause…
December 21, 2023

Read more

VIEWPOINTS_Betty Woo_2023
VIEWPOINTS

In an Insightful Conversation with PharmaShots, Betty Woo Highlights Thermo Fisher’s Cell Therapy Collaboration Program

Shots:   Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio    Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program   Betty believes that through innovation and partnership, they can tap into the full…
November 30, 2023

Read more

Load more